Últimas noticias sobre Scilex Holding (NASDAQ:SCLX) Bolsa

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Scilex Holding Co

Earnings

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported fourth-quarter revenue of $39.3 billion, representing an extraordinary growth trajectory that has seen quarterly revenue multiply nearly eight times in just five years, according to data shared Wednesday by The Kobeissi Letter.
What Happened: The chipmaker&#8217;s daily revenue reached $427 million throughout the fourth quarter, with data center sales—primarily from AI-focused GPUs—surging 93% year-over-year to $35.6 billion, now accounting for over 90% of total revenue.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia&#39;s, <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>, Q4 Revenue by Year: 1. 2015: $1.4B 2. 2016: $2.2B 3. 2017: $2.9B 4. 2018: $2.2B 5. 2019: $3.1B 6. 2020: $5B 7. 2021: $7.6B 8. 2022: $6.1B 9. 2023: $22.1B 10. 2024: $39.3B Nvidia&#39;s Q4 2024 revenue of $39.3 billion is now nearly 8 TIMES higher than it was 5 years…
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1894862360029929924?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite beating analyst expectations with earnings per share of $0.89 versus $0.84 expected and revenue exceeding forecasts by $1 billion, NVDA shares traded slightly lower after the announcement, continuing a pattern of muted post-earnings reactions.
Analyst John Kicklighter noted that the stock exhibited &#8220;lots of volatility, but no clear direction,&#8221; with a range of approximately 8% from the spot relative to Nvidia.
RiskReversal Co-Founder Guy Adami expressed concern about potential margin deceleration, <a href="https://www.cnbc.com/video/2025/02/26/fast-money-traders-talk-nvidia-q4-results.html">telling</a> CNBC, &#8220;If margins start to decelerate, that&#8217;s when these stories typically get long in the tooth.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia earnings beats versus expectations. &#8211; EPS of $0.89 vs $0.84 expected &#8211; Revenue of $39.3 Bln vs $38.3 Bln expected Lot&#39;s of volatility, but no clear direction. Range of ~8% of spot from <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>: <a href="https://t.co/r4n2r0ZqU1">pic.twitter.com/r4n2r0ZqU1</a>
&mdash; John Kicklighter (@JohnKicklighter) <a href="https://twitter.com/JohnKicklighter/status/1894863290414535071?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: CEO Jensen Huang highlighted increasing computational demands in AI, saying that next-generation models require &#8220;100 times more compute&#8221; than earlier versions. He specifically cited DeepSeek&#8217;s R1, OpenAI&#8217;s GPT-4, and xAI&#8217;s Grok 3 as examples of models using <a href="https://www.benzinga.com/markets/equities/25/02/43995515/jensen-huang-says-deepseek-was-fantastic-next-gen-models-demand-100x-more-compute-as-nvidia-smashes-earnings-records">intensive reasoning processes</a>.
&#8220;DeepSeek was fantastic,&#8221; Huang said, praising its open-source reasoning model despite the company&#8217;s stock dropping 17% in January over concerns that DeepSeek had found ways to achieve better AI performance with lower infrastructure costs.
Nvidia forecasts <a href="https://www.benzinga.com/news/earnings/25/02/43991607/nvidia-q4-earnings-highlights-revenue-beat-eps-beat-demand-for-blackwell-is-amazing">first-quarter revenue</a> of $43 billion, topping estimates of $41.75 billion. Huang says Blackwell AI supercomputers saw &#8220;billions in sales&#8221; in their first quarter as the company ramped up &#8220;massive-scale production.&#8221;
NVDA currently has a consensus price target of $172.28 based on 40 analysts, with recent targets from Rosenblatt, Morgan Stanley, and Tigress Financial implying a potential 52.59% upside.
<figure class="wp-block-image aligncenter size-full is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27023437/Screenshot-2025-02-27-at-1.03.40%E2%80%AFPM.png" alt="" class="wp-image-800908" style="width:703px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43995014/elon-musks-influence-over-the-government-set-to-increase-trump-orders-all-federal-agencies-to-appoint-a-doge-commissar">Elon Musk&#8217;s Influence Over The Government Set To Increase, Trump Orders All Federal Agencies To Appoint A DOGE Commissar</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

News

Markets

NVDA

Nvidia's Q4 Revenue Surges Over 78%, Nearly 8x Higher Than 5 Years Ago: Analysts Debate Stock's Next Move As Jensen Huang Says Blackwell Production Has Been Ramped Up

The Donald Trump administration is contemplating the withdrawal of a $590 million contract previously granted to&nbsp;Moderna Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) by the Biden administration. This contract was intended for the production of a bird flu vaccine.
What Happened: The U.S. health officials are currently scrutinizing Moderna&#8217;s avian flu vaccine contract as part of a broader review of government expenditure on messenger RNA-based vaccines, <a href="https://www.benzinga.com/news/25/02/43913228/trump-team-weighs-pulling-funding-for-moderna-bird-flu-vaccine">Bloomberg</a> reported. The contract, awarded during the final days of the Biden administration, shot up Moderna&#8217;s stock within two days of the announcement on January 17.
A spokesperson from Robert F. Kennedy Jr.-led Department of Health and Human Services (HHS) communicated that the review was necessitated by &#8220;four years of the Biden administration's failed oversight.&#8221; The spokesperson acknowledged the criticality of readiness for the pandemic but also underscored the need for careful examination of vaccine production contracts.
Moderna, having successfully completed an initial trial of the bird flu vaccine last year,&nbsp;was preparing for a&nbsp;large-scale final-stage trial. However, the absence of funding might impede the trial&#8217;s progress. The company has been grappling with the need to identify new revenue streams as the sales of its COVID-19 vaccine decline and it maintains significant investments in its pipeline.
The contract was hastily approved amid apprehensions that the Trump administration might be less inclined to finance vaccine manufacturers. Moderna has also been involved in a patent dispute with the National Institutes of Health regarding its vaccine.
SEE ALSO: <a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs</a>
Why It Matters: The reconsideration of funding comes at a time when the Trump administration has <a href="https://www.benzinga.com/markets/25/02/43998434/trump-team-commits-1-billion-to-combat-bird-flu-lower-egg-prices-hopefully-by-summer-says-usda">committed $1 billion </a>to fight bird flu and bring down the rising egg prices. Notably, the commitment also includes an allocation of $100 million for vaccine research, though the poultry industry is divided on its implications. 
This development also coincides with a phase when influential personalities like <a href="https://www.benzinga.com/personal-finance/25/02/43913228/bill-gates-says-next-pandemic-can-emerge-anywhere-and-the-world-isnt-prepared-we-cant-afford-to-get-caught-flat-footed-again">Bill Gates</a> have warned about the potential for new pandemics and the world&#8217;s lack of preparedness. Gates has emphasized that we cannot afford to be caught off guard again, particularly after the devastating impact of COVID-19.
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html" target="_blank" rel="noreferrer noopener">reports</a>. Through his nonprofit, Children&#8217;s Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies" target="_blank" rel="noreferrer noopener">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
Moderna stock has plunged over 65% during the last 12 months as per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
READ MORE: <a href="https://www.benzinga.com/25/02/43998608/tesla-continuing-to-upgrade-its-headquarters-in-texas-says-exec">Elon Musk&#8217;s Tesla Upgrades Giga Texas: Driverless Cars, Cybercab Preparations, GPU Training Cluster And More</a>

MRNA

Trump's Officials To Re-Consider Moderna's $590 Million Bird Flu Vaccine Funding: RFK Jr-Led HHS Slams 'Biden Administration's Failed Oversight'

"This feedstock allocation is a vital step in our collaboration with Sipchem," said Peter Vanacker, LyondellBasell chief executive officer. "As we move forward with our joint study, with a long-term partnership in mind, we further strengthen our commitment to Saudi Arabia. Thank you to the Ministry of Energy for their support and collaboration as we build on our successful partnership. We look forward to being a larger part of the Kingdom's thriving economy, which continues to grow and provide numerous opportunities for development and innovation."

Sipchem And LyondellBasell Advance Petrochemical Ambitions With Saudi Energy Ministry's Feedstock Allocation

IPOs

Reported Earlier, Luda Technology Group Prices $10M Initial Public Offering Of 2.5M Ordinary Shares At $4/Share

VMAR

Vision Marine Signs Three-Year Exclusive Deal With STERK, Expanding European Electric Boat Market

&nbsp;Indivior PLC (Nasdaq/LSE: INDV)&nbsp;has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May 2025.

Management

INDV

Indivior Appoints Joseph Ciaffoni As New CEO, Effective Upon Shareholder Approval In May 2025

<ul>
<li>An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy analysis; trial completion expected by Q4 2025 (including a three-month follow-up period)</li>
<li>Tinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan for Stargardt disease, for which there are no approved treatments</li>
</ul>

BLTE

Belite Bio's Tinlarebant Trial For Stargardt Disease Advances As DSMB Recommends Continuation Without Modifications

DTEGY

Nokia and Deutsche Telekom's T Wholesale Partner To Expand Network API Market, Empowering Developers

Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube revealed that it has reached over 1 billion monthly active viewers of podcast content, thus outperforming Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>).
What Happened: In a blog post published on Thursday, YouTube said it is now the most popular service for podcast listening in the U.S. It added that last year, viewers spent over 400 million hours each month watching podcasts on living room devices.
YouTube&#8217;s distinctive search and recommendation features have simplified the process for users to discover new podcasts. Additionally, the platform has broadened its&nbsp;revenue-sharing program, the YouTube&nbsp;Partner Program, to accommodate more podcasters.
Research from Edison Podcast Metrics in October indicated that&nbsp;about 31% of weekly podcast&nbsp;listeners in the U.S. favor YouTube, compared to 27% for Spotify and 15% for Apple Podcasts by Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). This surge in growth occurred after Google Podcasts was discontinued in mid-2024.
Celebrating YouTube&#8217;s 20th anniversary on Feb 11, CEO Neal Mohan pledged to introduce more tools to assist podcasters and enhance monetization for creators. The platform also intends to further simplify podcast discovery for users.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43995014/elon-musks-influence-over-the-government-set-to-increase-trump-orders-all-federal-agencies-to-appoint-a-doge-commissar">Elon Musk&#8217;s Influence Over The Government Set To Increase, Trump Orders All Federal Agencies To Appoint A DOGE Commissar</a>
Why It Matters: The platform&#8217;s success in the podcast sector further underscores its growing influence and potential for increased revenue generation. It is noteworthy that with 1 billion monthly podcast listeners, YouTube has surpassed Spotify&#8217;s count of 675 million monthly active users in 2024. 
YouTube recognized podcasts as a trending content format during the pandemic. After investing billions in its podcasting segment, Spotify shut its in-house podcast studio, Studio 4 in 2022 and laid off staff. It was during that time that YouTube started offering up to $300,000 to podcasters as an incentive to produce video versions of their shows, stated Bloomberg.
Meanwhile, YouTube remains an integral part of Google&#8217;s Service segment. During Alphabet&#8217;s fourth quarter results, CEO Sundar Pichai stated, &#8220;Our AI-powered Google Cloud portfolio is seeing stronger customer demand, and YouTube continues to be the leader in streaming watchtime and podcasts.&#8221; Google&#8217;s Service segment contributes over 87% of the company&#8217;s total revenue. 
Needham analysts estimate that based on a sum-of-the-parts valuation,<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43506569/alphabet-stock-should-trade-at-a-premium-5-analysts-highlight-ai-capex-how-much-youtube-could-be-worth"> YouTube is worth $666 billion</a>, or around $54 per share in case Alphabet spins off or separates the highly coveted asset.&nbsp;
The expansion of the YouTube Partner Program also indicates a strategic move to attract more creators and diversify content, which could further boost the platform&#8217;s value.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/tech/25/02/43997658/toyota-records-first-worldwide-production-increase-in-a-year-but-sales-remain-stagnant-in-january">Toyota Records First Worldwide Production Increase In A Year, But Sales Remain Stagnant In January</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

GOOG

GOOGL

SPOT

YouTube Beats Out Spotify As Top Podcast Platform With 1 Billion Users, CEO Promises Bigger Paydays For Creators

BWLP

BW LPG Reported Q4 EPS $0.22 Down From $1.14 YoY, Profit After Tax $39.7M Down From $161.8M YoY

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) executive Omead Afshar said earlier this week that the EV giant is continuing to upgrade its <a href="https://www.benzinga.com/general/entertainment/24/01/36463904/how-big-will-teslas-expanded-giga-texas-be-musk-says-pretty-close-to-length-of-a-star-destr">gigafactory in Texas</a> with infrastructural and technological improvements.
What Happened: &#8220;Exciting things continuing at Giga Texas!,&#8221; Afshar said in a post on X on Tuesday. 
The factory has now been upgraded to produce the company&#8217;s refreshed Model Y, Afshar said. <a href="https://www.benzinga.com/news/24/06/39245293/elon-musks-boring-company-is-making-a-tunnel-at-giga-texas-for-transporting-cybertrucks">A tunnel</a> runs under the highway to reduce travel by a kilometer from the end of the production line to the logistics yard, he said, while adding that driverless cars have started driving from the factory directly to the specific outbound lane where they will be loaded onto a truck for delivery.
Preparation is also underway for the start of Cybercab volume production at the factory starting in 2026, he said. 
Afshar is a vice president in charge of sales and manufacturing with senior executives in North America and Europe reporting to him, The Wall Street Journal <a href="https://www.benzinga.com/news/24/10/41378568/tesla-promotes-key-executives-and-gives-them-more-responsibilities-in-leadership-shuffle">reported</a> in October. He is one of the few executives with a Tesla-affiliated tag on Elon Musk&#8217;s social media platform X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Exciting things continuing at Giga Texas! a capacity for &gt;250,00 Model Y's. &#8211; the new Model Y &#8211; Cybertruck's all built at Giga Texas &#8211; a ~50k GPU training cluster, Cortex, that has helped enable V13 of FSD &#8211; a tunnel under the highway reducing travel by 1,000m from from the… <a href="https://t.co/vtImO5gjOO">https://t.co/vtImO5gjOO</a> <a href="https://t.co/gKYzUc5XbS">pic.twitter.com/gKYzUc5XbS</a>
&mdash; Omead Afshar (@omead) <a href="https://twitter.com/omead/status/1894500838107930876?ref_src=twsrc%5Etfw">February 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Giga Texas is Tesla&#8217;s global headquarters which covers 2500 acres along the Colorado River with over 10 million square feet of factory floor,&nbsp;offering considerable potential for further expansion.
The plant is the manufacturing hub for both Tesla&#8217;s best-selling Model Y SUV as well as its stainless steel Cybertruck. According to Tesla&#8217;s last quarterly report, the company can produce over 250,000 Model Ys in a year and over 125,000 Cybertrucks.
Tesla is also incorporated in Texas. The company&#8217;s stockholders approved the move last year after company CEO Musk soured on Delaware.
&#8220;Texas and Nevada are the best choices for incorporation,&#8221; Musk said earlier this month.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43967170/lucids-interim-ceo-clarifies-on-peter-rawlinsons-earlier-statement-doesnt-mean-we-are-deprioritizing-our-automotive-car-business" target="_blank" rel="noreferrer noopener">Lucid's Interim CEO Clarifies On Peter Rawlinson's Earlier Statement: ‘Doesn't Mean We Are Deprioritizing Our Automotive Car Business'</a></li>
</ul>
Photo courtesy: Shutterstock

TSLA

Elon Musk's Tesla Upgrades Giga Texas: Driverless Cars, Cybercab Preparations, GPU Training Cluster And More

CJET

Reported Earlier, Chijet Motor Receives Nasdaq Delisting Determination, Cites Market Value Compliance Issues

LZMH

Reported Earlier, LZ Technology Holdings Prices $7.2M Initial Public Offering Of 1.8M Class B Ordinary Shares At $4/Share

CWAN

ENFN

Reported Earlier, Clearwater-Enfusion Deal Progresses As Hart-Scott-Rodino Antitrust Waiting Period Ends

WETO

Reported Earlier, Webus International Limited Prices $8M Initial Public Offering Of 2M Ordinary Shares At $4/Share

The administration under President Donald Trump is preparing to channel up to $1 billion into measures to counter the persistent bird flu epidemic or avian influenza (HPAI) and augment egg imports, in an attempt to address skyrocketing prices.
What Happened: U.S. Agriculture Secretary&nbsp;Brooke Rollins&nbsp;revealed the funding strategy, which is a response to a three-year bird flu crisis that has led to the demise of&nbsp;approximately 166 million chickens, according to USDA data. The virus has also impacted close to 1,000 dairy herds and infected nearly 70 people, resulting in one reported death since early 2024.
The USDA plans to assign up to $500 million for complimentary biosecurity audits for&nbsp;farms and a sum of $400 million to&nbsp;enhance compensation rates for farmers who need to eliminate their chickens due to the flu, stated Rollins at a state agriculture officials conference. The funding will come from the USDA&#8217;s Commodity Credit Corporation, a discretionary fund accessible to the secretary, explained by Rollins&#8217; chief of staff, Kailee Tkacz Buller, as per Reuters.
Rollins further stated that other strategies include $100 million allocated for vaccine research, efforts to ease regulatory burdens on the egg and chicken industry, and consideration of temporary import solutions.
Although the USDA is contemplating vaccines for chickens, they have not received approval yet. Opinions in the poultry industry are split on this issue due to possible trade impacts. The administration also plans to increase egg imports and reduce exports to strengthen the domestic supply and combat record-high egg prices. Turkey has committed to exporting 15,000 tons of eggs to the U.S. by July, a move expected to substantially boost the nation&#8217;s egg supply.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43980072/theres-no-reason-to-spend-1-trillion-on-the-military-trumps-statement-sends-us-defense-stocks-spiraling-while-europes-surge">&#8216;There&#8217;s No Reason To Spend $1 Trillion On The Military&#8217;—Trump&#8217;s Statement Sends US Defense Stocks Spiraling While Europe&#8217;s Surge</a>
Why It Matters: This move comes in the wake of a recent debate over food affordability solutions, sparked by prominent economic commentator Noah Smith. As egg prices hit record levels, Smith mocked President Donald Trump and suggested <a href="https://www.benzinga.com/markets/equities/25/02/43905413/trump-economy-as-egg-prices-soar-economist-mocks-shift-to-chickpeas">alternatives to eggs</a>, such as chickpeas. 
High egg prices have been a key cause of the inflation in the country. The most recent monthly consumer price index revealed that the average cost of a dozen Grade A eggs in U.S. cities rose to $4.95 in January. Specialty options, like organic and cage-free eggs, come at an even higher price. On Wednesday, the USDA predicted that egg prices, already at record highs, could surge by over 40% in 2025.
The USDA&#8217;s plan to increase egg imports, particularly from Turkey, is expected to alleviate the current egg shortage and stabilize prices.
That being said, Rollins acknowledged, "It's going to take a while to get through, I think in the next month or two, but hopefully by summer.&#8221; Rollins is also confident that the USDA will have sufficient staff to respond to bird flu, despite the DOGE-led federal workforce reductions.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43995515/jensen-huang-says-deepseek-was-fantastic-next-gen-models-demand-100x-more-compute-as-nvidia-smashes-earnings-records">Jensen Huang Says &#8216;DeepSeek Was Fantastic:&#8217; Next-Gen Models Demand 100x More Compute As Nvidia Smashes Earnings Records</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Team Commits $1 Billion To Combat Bird Flu, Lower Egg Prices: 'Hopefully By Summer', Says USDA

Reported Earlier, RenaissanceRe's Joint Venture DaVinciRe Prices $300M Senior Notes Offering At 5.950% Due 2035

Preliminary Financial Results
Fourth Quarter 2024
Preliminary Revenues are expected to be in the range of $12,700,000 to $13,000,000 for the fourth quarter of 2024 compared with $10,773,000 for the fourth quarter of 2023, a year-on-year increase of between 17.9% and 20.7%.
Preliminary Gross margin is expected to be in the range of 46.7% to 47.7% for the fourth quarter of 2024 compared with 43.6% for the fourth quarter of 2023.
Fiscal Year 2024
Preliminary Revenues are expected to be in the range of $48,907,000 to $49,207,000 in 2024 compared with $41,168,000 in 2023. This represents an annual increase of between 18.8% and 19.5%. This will mark three consecutive years of close to 20% growth per annum.
Preliminary Gross margin is expected to be in the range of 46.0% to 46.3% in 2024 compared with 40.7% in 2023. Over the past three years, the Company's gross margin has increased over 1,000 basis points.
"These results reflect the strength of our strategy, the dedication of our team, and the trust of our customers," said Cameron Pforr, Mtron Interim Chief Executive Officer and Chief Financial Officer. "During fiscal year 2024, we raised our guidance twice and we are proud of our strong performance, which exceeded the last round of guidance. We remain focused on driving sustainable growth and delivering value for our shareholders."

MPTI

Reported Earlier, M-Tron Industries Reports Preliminary Q4 Revenue Expectation Of $12.7M-$13M And Full-Year 2024 Of $48.907M-$49.207M

Postal Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTL#NYSE">PSTL</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.23 by 52.17 percent. This is a 34.62 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $21.37 million which beat the analyst consensus estimate of $18.32 million by 16.62 percent. This is a 25.69 percent increase over sales of $17.00 million the same period last year.

Earnings Beats

PSTL

Postal Realty Trust Q4 2024 FFO $0.35 Beats $0.23 Estimate, Sales $21.37M Beat $18.32M Estimate

Health Care

Press Releases

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

General

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Contracts

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Dividends

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

DECA

SCLX

SRNE

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

NRX Pharmaceuticals

Nutriband

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

VYNE Therapeutics

D. Boral Capital

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

Biotech

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Comments

Scilex Holding

Noticias

Últimas noticias sobre Scilex Holding (NASDAQ:SCLX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL